You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

XZP-3621

Showing 1 - 17 of 17
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Volunteers Trial in Suzhou ([14C]XZP-3621)

Not yet recruiting
  • Healthy Volunteers
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Suzhou Universiy
Apr 19, 2023

Healthy Subjects Trial in Qingdao (XZP-3621 tablet and itraconazole oral liquid (for Arm1), XZP-3621 tablet and Rifampicin

Not yet recruiting
  • Healthy Subjects
  • XZP-3621 tablet and itraconazole oral liquid (for Arm1)
  • +2 more
  • Qingdao, Shan Dong, China
    The Affiliated Hospital of Qingdao University
Oct 16, 2022

ALK-positive NSCLC Trial in Jilin (XZP-3621)

Not yet recruiting
  • ALK-positive NSCLC
  • XZP-3621
  • Jilin, Chang Chun, China
    Jilin Province Cancer Hospital
Jul 29, 2022

Healthy Trial in Qingdao (XZP-3621)

Not yet recruiting
  • Healthy
  • XZP-3621
  • Qingdao, Shandong, China
    The Affiliated Hospital of Qingdao University
Aug 27, 2021

NSCLC Trial in Chang Chun (XZP-3621, Crizotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Chang Chun, Ji Lin, China
    Jilin Province Cancer Hospital
Jan 10, 2022

ROS1 Rearrangement NSCLC, ALK Rearrangement NSCLC Trial in ShangHai (XZP-3621)

Recruiting
  • ROS1 Rearrangement Non-small Cell Lung Cancer
  • ALK Rearrangement Non-small Cell Lung Cancer
  • XZP-3621
  • ShangHai, Shanghai, China
    Shanghai Chest hospital affiliated to Shanghai jiao tong univers
Sep 14, 2021

Healthy Male Subjects Trial in Beijing ([14C]XZP-3287)

Not yet recruiting
  • Healthy Male Subjects
  • Beijing, Beijing, China
    Beijing Gaobo Boren Hospital
Jul 25, 2022

Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Locally Advanced or Metastatic Non-small Cell Lung Cancer
  • XZP-5955 tablets
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
May 17, 2022

Healthy Trial in Bengbu (XZP-3287 combined with clarithromycin, XZP-3287 combined with rifampicin)

Recruiting
  • Healthy
  • XZP-3287 combined with clarithromycin
  • XZP-3287 combined with rifampicin
  • Bengbu, Anhui, China
    The First Affiliated Hospital of Bengbu Medical College
Jul 20, 2021

Advanced Breast Cancer Trial in Harbin (XZP-3287+ Letrozole/Anastrozole, Placebo + Letrozole/Anastrozole)

Not yet recruiting
  • Advanced Breast Cancer
  • XZP-3287+ Letrozole/Anastrozole
  • Placebo + Letrozole/Anastrozole
  • Harbin, Heilongjiang, China
    Harbin Medical University Cancer Hospital
Feb 16, 2022

Advanced Breast Cancer Trial in Beijing (XZP-3287+Fulvestrant, Placebo + Fulvestrant)

Recruiting
  • Advanced Breast Cancer
  • Beijing, Beijing, China
    Chinese Academy of Medical Science
Jan 4, 2022

Healthy Trial in Qingdao (XZP-3287)

Recruiting
  • Healthy
  • Qingdao, Shandong, China
    The Affiliated Hospital of Qingdao University
Jul 20, 2021

Non-alcoholic Fatty Liver Disease Trial in Beijing (XZP-6019 tablet, Placebo)

Not yet recruiting
  • Non-alcoholic Fatty Liver Disease
  • XZP-6019 tablet
  • Placebo
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Sep 30, 2021

Nonalcoholic Steatohepatitis (NASH) Trial in Beijing (XZP-5610 Tablet (for Part A), Placebo to match XZP-5610 Tablet (for Part

Recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • XZP-5610 Tablet (for Part A)
  • +5 more
  • Beijing, China
    Peking University Third Hospital
Jun 2, 2021

Non Small Cell Lung Cancer Trial in China (XZP-5809-TT1 Tablet)

Recruiting
  • Non Small Cell Lung Cancer
  • XZP-5809-TT1 Tablet
  • Beijing, Beijing, China
  • +4 more
Mar 17, 2021

Healthy Subject Trial in Beijing (Fadanafil, Placebo)

Completed
  • Healthy Subject
  • Beijing, Beijing, China
    Haiyan Li
Mar 16, 2020

Metastasis Solid Tumors, Advanced Breast Cancer Trial in Beijing (XZP-3287)

Unknown status
  • Metastasis Solid Tumors
  • Advanced Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 3, 2020